Trial Information

Summary: Clinical trial to test a study drug in HIV treatment

This study is to evaluate the effectiveness of a new integrase inhibitor (in an expanded access program [EAP]) with FuzeonŽ (enfuvirtide) in people infected with HIV-1 who have already been treated with medicines from three other HIV drug classes.

To qualify, you must:

• Be positive for HIV-1
• Be at least 18 years old
• Be enrolled in an expanded access program for an integrase inhibitor
• Have received treatment for the HIV-1 virus
• Have a viral load higher than 1,000 copies/mL within the past month
• Be able to self-inject the study drug twice a day, or have a reliable care giver who is willing, able and available to assist you with this for the duration of the study

You will not qualify if you:

• Are pregnant or breast-feeding
• Have participated in a clinical trial within the last 30 days

If you would like to learn more about participating in this study, please send an e-mail message using the form below.